References
- Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: report of the third Nationwide Study. Korean J Pathol 2011;45:254-60. https://doi.org/10.4132/KoreanJPathol.2011.45.3.254
- Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of firstline management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012; 30:3368-75. https://doi.org/10.1200/JCO.2011.40.6546
- Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Netw 2014;12: 916-46. https://doi.org/10.6004/jnccn.2014.0086
- Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24:561-76. https://doi.org/10.1093/annonc/mds517
- Guadagnolo BA, Li S, Neuberg D, et al. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006;64:928-34. https://doi.org/10.1016/j.ijrobp.2005.08.010
- Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumorburden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-7. https://doi.org/10.1200/JCO.1997.15.3.1110
- Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-22. https://doi.org/10.1016/S0140-6736(03)14110-4
- Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32. https://doi.org/10.1182/blood-2005-01-0016
- Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23. https://doi.org/10.1182/blood-2004-08-3175
- Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92. https://doi.org/10.1200/JCO.2006.06.4618
- Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31. https://doi.org/10.1182/blood-2008-04-153189
- Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86. https://doi.org/10.1200/JCO.2007.13.5376
- Russo AL, Chen YH, Martin NE, et al. Low-dose involvedfield radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys 2013;86:121-7. https://doi.org/10.1016/j.ijrobp.2012.12.024
- Hoskin PJ, Kirkwood AA, Popova B, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol 2014; 15:457-63. https://doi.org/10.1016/S1470-2045(14)70036-1
- Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27: 4555-62. https://doi.org/10.1200/JCO.2008.21.3991
- Bastion Y, Berger F, Bryon PA, Felman P, Ffrench M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991;2 Suppl 2:123-9. https://doi.org/10.1093/annonc/2.suppl_2.123
- Leonard RC, Hayward RL, Prescott RJ, Wang JX. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma: the Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol 1991;2:655-62. https://doi.org/10.1093/oxfordjournals.annonc.a058044
- Decaudin D, Lepage E, Brousse N, et al. Low-grade stage IIIIV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients: a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999;17:2499-505. https://doi.org/10.1200/JCO.1999.17.8.2499
- Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783-9.
- Solal-Celigny, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65. https://doi.org/10.1182/blood-2003-12-4434
- Federico M, Guglielmi C, Luminari S, et al. Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens: a GISL study. Haematologica 2007;92:1482-8. https://doi.org/10.3324/haematol.11502
- Frank C, Zierhut D, Schulz-Ertner D, Wannenmacher M. Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy. Strahlenther Onkol 2001;177:597-603. https://doi.org/10.1007/PL00002370
- Ha CS, Kong JS, Tucker SL, et al. Central lymphatic irradiation for stage I-III follicular lymphoma: report from a singleinstitutional prospective study. Int J Radiat Oncol Biol Phys 2003;57:316-20. https://doi.org/10.1016/S0360-3016(03)00592-3
- Ahmed N, Owen TE, Rubinger M, et al. Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone. PLoS One 2013;8:e65156. https://doi.org/10.1371/journal.pone.0065156
- Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002;20:4261-7. https://doi.org/10.1200/JCO.2002.08.674
- Bachy E, Houot R, Morschhauser F, et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVPinterferon plus rituximab in follicular lymphoma. Haematologica 2013;98:1107-14. https://doi.org/10.3324/haematol.2012.082412
- Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013;31:1506-13. https://doi.org/10.1200/JCO.2012.45.0866
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10. https://doi.org/10.1016/S0140-6736(12)61763-2
- Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944-52. https://doi.org/10.1182/blood-2013-11-531327
- De Los Santos JF, Mendenhall NP, Lynch JW Jr. Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 1997;38:3-8. https://doi.org/10.1016/S0360-3016(96)00631-1
- McClanahan F, Hielscher T, Rieger M, et al. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy. Eur J Haematol 2010;85:11-9.
Cited by
- Treatment outcome of diffuse large B-cell lymphoma involving the head and neck : Two-institutional study for the significance of radiotherapy after R-CHOP chemotherapy vol.96, pp.25, 2015, https://doi.org/10.1097/md.0000000000007268
- Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis vol.11, pp.1, 2021, https://doi.org/10.1038/s41598-021-01851-w